Cargando…

Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study

We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015....

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Jiang, Du, Shuxu, Dai, Guorui, Gao, Guiju, Yang, Di, Zhao, Hongxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432515/
https://www.ncbi.nlm.nih.gov/pubmed/28507339
http://dx.doi.org/10.1038/s41598-017-02086-4
_version_ 1783236643285630976
author Xiao, Jiang
Du, Shuxu
Dai, Guorui
Gao, Guiju
Yang, Di
Zhao, Hongxin
author_facet Xiao, Jiang
Du, Shuxu
Dai, Guorui
Gao, Guiju
Yang, Di
Zhao, Hongxin
author_sort Xiao, Jiang
collection PubMed
description We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33.3% versus 5.9%), and sepsis (20% versus 5.9%) (p < 0.05). In the BL group, 10 (66.7%) patients died from treatment-related or tumour-related causes, 5 (33.3%) achieved complete response, 1 achieved partial response (6.7%), and 7 developed progressive disease. The 1-year overall survival and progression-free survival rates were 33.3%. Of the DLBCL patients, 3 (17.6%) died from treatment-related causes, 14 (82.4%) achieved complete response, and 3 had progressive disease. The 1-year overall survival and progression-free survival rates were 82.4%. The strongest risk factor for death was relapse between chemotherapy cycles (adjusted hazard ratio = 47.3; 95%CI, 4.2–528.6, p = 0.002). Initiating antiretroviral therapy before chemotherapy failed to improve overall survival. DLBCL patients demonstrated good responses and survival outcomes, while BL patients could not tolerate chemotherapy due to more severe toxicity, and showed poor responses and survival outcomes.
format Online
Article
Text
id pubmed-5432515
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-54325152017-05-17 Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study Xiao, Jiang Du, Shuxu Dai, Guorui Gao, Guiju Yang, Di Zhao, Hongxin Sci Rep Article We evaluated the efficacy and tolerability of chemotherapy in HIV-infected patients with diffuse large B-cell lymphoma (DLBCL) receiving CHOP ± R (n = 17) or Burkitt lymphoma (BL) receiving CODOX-M/IVAC ± R (n = 15). The study was conducted in Beijing Ditan Hospital from January 2009 to August 2015. The following grade 4 adverse effects were observed in BL and DLBCL patients, respectively: neutropenia (80% versus 47.1%), anaemia (46.7% versus 5.9%), thrombocytopenia (53.3% versus 11.8%), bacterial pneumonia (33.3% versus 5.9%), and sepsis (20% versus 5.9%) (p < 0.05). In the BL group, 10 (66.7%) patients died from treatment-related or tumour-related causes, 5 (33.3%) achieved complete response, 1 achieved partial response (6.7%), and 7 developed progressive disease. The 1-year overall survival and progression-free survival rates were 33.3%. Of the DLBCL patients, 3 (17.6%) died from treatment-related causes, 14 (82.4%) achieved complete response, and 3 had progressive disease. The 1-year overall survival and progression-free survival rates were 82.4%. The strongest risk factor for death was relapse between chemotherapy cycles (adjusted hazard ratio = 47.3; 95%CI, 4.2–528.6, p = 0.002). Initiating antiretroviral therapy before chemotherapy failed to improve overall survival. DLBCL patients demonstrated good responses and survival outcomes, while BL patients could not tolerate chemotherapy due to more severe toxicity, and showed poor responses and survival outcomes. Nature Publishing Group UK 2017-05-15 /pmc/articles/PMC5432515/ /pubmed/28507339 http://dx.doi.org/10.1038/s41598-017-02086-4 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Xiao, Jiang
Du, Shuxu
Dai, Guorui
Gao, Guiju
Yang, Di
Zhao, Hongxin
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_full Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_fullStr Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_full_unstemmed Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_short Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study
title_sort efficacy and tolerability of chemotherapy in chinese patients with aids-related burkitt lymphoma and diffuse large b-cell lymphoma: an observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432515/
https://www.ncbi.nlm.nih.gov/pubmed/28507339
http://dx.doi.org/10.1038/s41598-017-02086-4
work_keys_str_mv AT xiaojiang efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy
AT dushuxu efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy
AT daiguorui efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy
AT gaoguiju efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy
AT yangdi efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy
AT zhaohongxin efficacyandtolerabilityofchemotherapyinchinesepatientswithaidsrelatedburkittlymphomaanddiffuselargebcelllymphomaanobservationalstudy